Skip to main content
Eli LillyPatent grant

Eli Lilly was granted a patent for KRAS G12C inhibitor compounds

Source: Autobound Signal API · 114 signals tracked for Eli Lilly · updated

Get Eli Lilly's live signals in Claude or ChatGPT, or by API

AskWhat changed at Eli Lilly this week? Use Autobound signals for lilly.com.

What happened

In November 2026 Eli Lilly patented drug candidates intended for treating cancer driven by KRAS G12C mutations.

Source

patents.google.comNov 17, 2026

US patent US12799133

KRas G12C inhibitors

Abstract

The present invention provides compounds of the formula: where R 1, R 2, R 3, R 4, R 5, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.

patents.google.com/patent/US12799133Read the full source

Extracted by Autobound

From the Signal API record
Signal
Patent grant

What this signalsA new patent often shows where a company is putting its R&D budget.

Grant date
Nov 17, 2026
Inventors
4
Patent number
US12799133
Assignee
Eli Lilly and Company

The full record

From the Signal API record

People

  • Serge Louis BouletInventor
  • Kevin Charles FortnerInventor
  • Deqi GuoInventor
  • David Michael HymanInventor
  • Sheng-Bin PengInventor
  • Chong SiInventor

Details

Primary CPC class
C07D 498/04
USPTO assignee
Eli Lilly and Company
What the invention does
A group of chemical compounds designed to block the KRAS G12C cancer target, along with their usable salt forms and treatment applications.

Topics and mentions

Tags

  • Intellectual Property
  • Research & Development
  • Pharmaceuticals
  • Medical Research

Technologies named

  • KRAS G12C inhibitors
  • small-molecule drugs
  • oncology

Extraction

Detected
Nov 18, 2026
signal_type
patents-company
signal_subtype
patentGrant

Use this data

Get every patent signal for Eli Lilly and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Eli Lilly this week?”

  2. Send it to your own tools

    The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/324e7c10-3460-5392-959e-0ea13cf0094e returns this record as JSON. POST /v1/companies/enrich returns every signal for lilly.com.

{
  "signal_id": "324e7c10-3460-5392-959e-0ea13cf0094e",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-11-18T15:07:09+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "cpc": [
      {
        "code": "C07D 498/04"
      },
      {
        "code": "A61K 31/4985"
      },
      {
        "code": "A61K 31/506"
      },
      {
        "code": "A61K 31/517"
      },
      {
        "code": "A61K 31/519"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Medical Research"
    ],
    "detail": "In November 2026 Eli Lilly patented drug candidates intended for treating cancer driven by KRAS G12C mutations.",
    "summary": "Eli Lilly was granted a patent for KRAS G12C inhibitor compounds",
    "event_at": "2026-11-17",
    "inventors": [
      {
        "name": "Serge Louis Boulet",
        "status": "resolved",
        "is_primary": true,
        "linkedin_url": "https://www.linkedin.com/in/serge-boulet-07318b145"
      },
      {
        "name": "Kevin Charles Fortner",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Deqi Guo",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "David Michael Hyman",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/dhymanmd"
      },
      {
        "name": "Sheng-Bin Peng",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/sheng-bin-peng-1b201a31"
      },
      {
        "name": "Chong Si",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/chong-si-31771b10"
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-11-17",
    "source_url": "https://patents.google.com/patent/US12799133",
    "cpc_primary": {
      "code": "C07D 498/04"
    },
    "patent_title": "KRas G12C inhibitors",
    "patent_number": "US12799133",
    "uspto_assignee": "Eli Lilly and Company",
    "patent_abstract": "The present invention provides compounds of the formula: where R 1 , R 2 , R 3 , R 4 , R 5 , A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.",
    "precision_class": "structural",
    "invention_explanation": "A group of chemical compounds designed to block the KRAS G12C cancer target, along with their usable salt forms and treatment applications.",
    "technologies_mentioned": [
      "KRAS G12C inhibitors",
      "small-molecule drugs",
      "oncology"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.